Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m. PT on Wednesday, May 13, 2026. Peter Griffith, executive vice president and chief ...

TAGMO Clinical Readouts -- Initial results for head and neck, and upper GI adenocarcinoma cohorts are expected midyear, with ...

Amgen Inc (AMGN) reports a robust 4% growth in product sales, driven by key growth drivers, while navigating patent expirations and increased competition.

Amgen raised its 2026 revenue and non-GAAP EPS guidance after a strong first quarter, driven by 24% growth from six key products. The company expanded its MariTide Phase III program to include ...

Amgen lifted its 2026 revenue and earnings guidance after a strong first quarter, driven by key growth products and pipeline advances like obesity drug MariTide. At the same time, researchers are ...

Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced ...

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent ...

Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's First Quarter 2026 Financial Results Conference Call. [Operator Instructions] As a reminder, today's call is being ...

Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...

Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a ...

Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom ...